Company news
Bolt Biotherapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 28, 2023
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
March 28, 2023
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
March 13, 2023
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 13, 2022
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
November 6, 2022
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 11, 2022
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 29, 2022
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
January 5, 2022
Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
December 15, 2021
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
December 5, 2021
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
December 1, 2021
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 8, 2021
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
September 7, 2021
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
August 25, 2021
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 11, 2021
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
June 3, 2021
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights
May 12, 2021
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
April 9, 2021
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 30, 2021
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 8, 2021
Calls
Decks
The 5 newest of 6 decks. Every deck is listed under its year.
- Merger or Acquisition (October 2026)
Merger or acquisition · 18 slides · Oct 23, 2026
- Investor Presentation (August 2026)
Investor deck · 24 slides · August 2026
- Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024
Conference · 15 slides · 2024
- ESMO Congress 2023
Conference · 9 slides · Oct 23, 2023
- ESMO Immuno-Oncology 2021
Conference · 24 slides · December 2021